Twice monthly (aspirational) recap of the NephJC journal club
The KDIGO Hypertension Guideline Draft
The KDIGO 2021 Hypertension Guidelines. We mixed things up and went with a Fantasy Football-style draft. Pick your favorite guideline, and remember not to take a kicker or a defense until the last rounds.
AKIKI-2 How soon is now?
Nephrology has been the recent beneficiary of a handful of studies examining the impact of the timing of the initiation of dialysis in AKI. One of these trials, AKIKI, now has a genuine sequel. In 2016 AKIKI was the first multi-center RCT examining early initiation of dialysis versus late initiation of dialysis and showed that early initiation not only did not improve patient outcomes but resulted in a significant number of patients receiving dialysis that would have recovered kidney function without intervention had they only been randomized to the late arm. Now five years later we are reviewing the sequel which asks the next logical question, “If delayed dialysis is as good as early dialysis is even later dialysis equivalent or better?”
The ASN Annual Fellow Survey, Covid 19 Edition
Episode 035: The COVID-19 Pandemic changed everything and last fall the ASN set out to document how it affected our nephrology fellows. The ASN Workforce Committee adapted the Annual Fellow Survey to assess how the pandemic affected nephrology fellows in terms of burn out, education, and enthusiasm for the specialty.
The CONFIRM Trial: Terliressin for Hepatorenal Syndrome
Episode 034: A newly expanded filtrate assembled to discuss the tricky CONFIRM Trial recently published in the NEJM. We are assisted by Elliot Tapper, noted hematologist and member of #LiverTwitter.
Roxadustat Statistical Rstate with Daniel Coyne
On April 6, 2021 Fibrogen announced that the analysis of the cardiovascular outcomes was adjusted after the data was unblinded. When the data was reanalyzed without this adjustment roxadustat is less impactful. Importantly for this NephJC discussion, the previously impressive MACE and MACE+ advantage for incident dialysis is no longer found. Roxadustat remains non-inferior in all outcomes, though the confidence intervals have widened.
NephMadness Bonus Podcast: Animal House
Animal House was one of the most exciting regions of NephMadness. We explore this region with the Selection Committee Member as well as the author to unlock the secrets of Animal House.